Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDEA.L Regulatory News (IDEA)

  • There is currently no data for IDEA

Board Changes

1 Jul 2020 07:00

RNS Number : 6223R
Ideagen PLC
01 July 2020
 

July 1st 2020

 

 

Ideagen PLC

("Ideagen" "the Company" or "the Group")

 

Board Change

 

Ideagen PLC (AIM: IDEA), a leading supplier of integrated risk management software to highly regulated industries, is pleased to confirm that Emma Hayes has today joined the Group as Chief Financial Officer, succeeding Graeme Spenceley, as announced on 7th January 2020.

 

Graeme has retired as a Director but will remain with the Group as Company Secretary and financial advisor to the Board. This role will be on a full-time basis until 31 October 2020 which will provide for a full and effective handover to Emma, and thereafter he will continue in that capacity on a part-time basis.

 

Emma was previously Group Finance Director, Capital Delivery and Commercial, at Severn Trent PLC having held the position since 2017. In this role she controlled a P&L and Balance Sheet of approximately ÂŁ600m and was responsible for driving operational efficiencies through her 100-strong team. Before that Emma spent 10 years with Deloitte LLP as a Corporate Finance Director where she led origination and execution of a wide range of M&A transactions. Emma qualified as a Chartered Accountant (ACA) with BDO.

Graeme Spenceley was previously awarded 750,000 share options under the Company's 2018 LTIP scheme (as announced on 29 March 2019 with details of the relevant scheme announced on 23 October 2018). The Board and Graeme have agreed that this award will be reduced to 187,500 options and that these will vest in full on the achievement of the first performance criteria (being the Company's share price reaching 196 pence over 30 consecutive business days).

Emma has in turn been awarded 562,500 share options under the 2018 LTIP with the same vesting conditions such that 187,500 of these options becoming eligible to vest on the first performance criterion described above being met, with the remainder becoming eligible to vest on the Company's share price reaching 259 pence over 30 consecutive business days. All other terms and conditions relating to the 2018 LTIP as previously described apply equally.

 

Ben Dorks, Chief Executive of Ideagen, commented; "Firstly, the Board would like thank Graeme for his outstanding commitment to Ideagen. His insight, acumen and support over the past 10 years has been invaluable and it has been a great pleasure to work alongside him. We are pleased that Graeme will remain with the business as Company Secretary which will provide for a robust transition.

 

The Board is delighted to welcome Emma to the Group who brings with her a deep understanding of both financial structures and processes and M&A. We will benefit hugely from Emma's experience and ability as Ideagen continues to execute its global growth strategy.''

 

There are no further disclosures to be made in relation to Emma Jane Hayes, aged 39, pursuant to Schedule 2(g) of the AIM Rules for Companies. .

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (MAR).

 

Enquiries:

Ideagen plc

01629 699100

David Hornsby, Executive Chairman

 

Ben Dorks, Chief Executive Officer

 

Graeme Spenceley, Chief Financial Officer

 

 

 

 finnCap Limited

020 7220 0500

Henrik Persson/James Thompson/ Hannah Boros (Nomad)

 

Alice Lane (ECM)

 

 

Canaccord Genuity Limited

 020 7523 8000

Simon Bridges

 

Richard Andrews

 

 

 

About Ideagen plc

Ideagen is a UK-headquartered, global technology company quoted on the London Stock Exchange AIM market (Ticker: IDEA.L).

The Group provides IRM software and services to organisations operating within highly regulated industries such as aviation, banking and finance and life science, with its main operational premises spread throughout the UK, EU, US, Middle East and SE Asia.

With an excellent portfolio of software products including Q-Pulse, Coruson, Pentana Audit and PleaseReview, Ideagen helps its clients reduce costs, improve operational efficiency, strengthen compliance and oversight and anticipate and manage every detail of risk.

Currently, more than 4,700 organisations use Ideagen's products including seven of the top 10 UK accounting firms, all of the top aerospace and defence companies and 75% of the world's leading pharmaceutical firms.

Ideagen's diverse and varied customer base includes many well-known, global brands such as British Airways, Aggreko, BAE, Ryanair, US Navy, KLM, BBVA, Bank of New York, Commerzbank, Meggitt, Heineken, Johnson Matthey, Haeco Group and European Central Bank. As well as this, Ideagen counts 180 hospitals across the UK and US amongst its client base.

For further information please visit www.ideagen.com

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Emma Hayes

2.

Reason for the notification

a)

Position/status:

Chief Financial Officer

b)

Initial notification/Amendment:

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

Ideagen plc

 

b)

LEI:

213800KS1MLITOVNYC85

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Identification code:

Ordinary shares of 0.1p

 

GB00B0CM0C50

b)

Nature of the transaction:

Grant of LTIPs over Ordinary Shares

c)

Price(s) and volume(s):

Price(s)

Volume(s)

n/a

562,500

 

d)

Aggregated information:

· Aggregated volume:

· Price:

See 4 (c) above

e)

Date of the transaction:

1 July 2020

 

f)

Place of the transaction:

Off market

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCFFFEIRLIIVII
Date   Source Headline
24th Sep 201810:42 amRNSHolding(s) in Company
17th Sep 20184:42 pmRNSExercise of Options and Total Voting Rights
17th Sep 20184:33 pmRNSHolding(s) in Company
13th Sep 20185:00 pmRNSClosing of conditional Placing to raise £20m
13th Sep 201811:30 amRNSProposed Placing to raise £20 million
5th Sep 20187:00 amRNSAcquisition of InspectionXpert Inc
3rd Sep 20182:36 pmRNSExercise of Options and Total Voting Rights
15th Aug 201812:23 pmRNSHolding(s) in Company
13th Aug 20183:18 pmRNSHolding(s) in Company
13th Aug 20183:05 pmRNSIssue of Shares under Share Incentive Plan and TVR
7th Aug 20181:08 pmRNSHolding(s) in Company
23rd Jul 20183:27 pmRNSIssue of Equity
17th Jul 20187:00 amRNSUnaudited Preliminary Results
18th Jun 20183:38 pmRNSExercise of Options and Total Voting Rights
11th Jun 20185:00 pmRNSIssue of Equity and Total Voting Rights
22nd May 20183:59 pmRNSIssue of Shares under Share Incentive Plan and TVR
15th May 20183:10 pmRNSExercise of Options and Total Voting Rights
9th May 20187:00 amRNSExercise of Options and Total Voting Rights
8th May 20187:00 amRNSPre-Close Trading Update and Board Changes
18th Apr 201810:12 amRNSIssue of Equity
12th Apr 201810:35 amRNSDirector/PDMR Shareholding
11th Apr 20187:00 amRNSDirector/PDMR Shareholding
6th Apr 20187:00 amRNSAcquisition of Medforce Technologies Inc
26th Mar 201812:38 pmRNSHolding(s) in Company
16th Mar 20187:00 amRNSIssue of Shares under Share Incentive Plan and TVR
6th Mar 20183:58 pmRNSExercise of Options and Total Voting Rights
14th Feb 20187:00 amRNSIssue of Equity
23rd Jan 20187:00 amRNSInterim Results
11th Jan 20187:00 amRNSIssue of Equity
13th Dec 201710:18 amRNSDirector Dealing
11th Dec 20172:26 pmRNSIssue of Equity
4th Dec 201712:37 pmRNSExercise of Options and Total Voting Rights
23rd Nov 20177:00 amRNSContract Win
10th Nov 20173:07 pmRNSIssue of Shares under Share Incentive Plan and TVR
7th Nov 20171:26 pmRNSExercise of Options and Total Voting Rights
7th Nov 20177:00 amRNSTrading Update
1st Nov 20175:18 pmRNSPDMR / PCA Dealing
30th Oct 20171:33 pmRNSResult of AGM
25th Oct 20177:00 amRNSExercise of Options and Total Voting Rights
23rd Oct 201710:55 amRNSExercise of Options and Total Voting Rights
16th Oct 20173:30 pmRNSExercise of Options and Total Voting Rights
9th Oct 20174:09 pmRNSIssue of shares under the Share Incentive Plan
6th Oct 20173:13 pmRNSNotice of AGM
27th Sep 20174:28 pmRNSExercise of Options and Total Voting Rights
20th Sep 201710:08 amRNSHolding(s) in Company
4th Sep 20177:00 amRNSBoard Appointment
1st Sep 20173:06 pmRNSIssue of shares under a Share Incentive Plan
11th Aug 20173:00 pmRNSHolding(s) in Company
11th Aug 20178:00 amRNSHolding(s) in Company
10th Aug 20171:36 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.